Table S1. Mean changes from baseline in the remaining individual NDI-K item scores.

Outcome	Week	Placebo (n = 44)	Low-dose HT074 (n = 43)	High-dose HT074 (n = 39)	*p*-value [1]	*p*-value [2]
Pain in upper abdomen	2	−2.5 ± 3.2‡	−2.6 ± 3.4‡	−3.1 ± 2.5‡	0.682	0.506
	4	−3.8 ± 3.1‡	−3.9 ± 3.2‡	−4.4 ± 2.7‡	0.956	0.532
	8	−4.8 ± 3.2‡	−4.1 ± 3.4‡	−4.3 ± 3.0‡	0.312	0.339
Burning in upper abdomen	2	−2.9 ± 2.7‡	−3.3 ± 2.8‡	−3.8 ± 3.1‡	0.486	0.068
	4	−4.2 ± 2.9‡	−4.0 ± 2.8‡	−3.8 ± 2.9‡	0.818	0.663
	8	−5.0 ± 2.9‡	−4.8 ± 3.0‡	−4.7 ± 2.6‡	0.962	0.786
Heartburn	2	−1.3 ± 3.2‡	−2.0 ± 3.3‡	−1.9 ± 3.6†	0.433	0.256
	4	−2.2 ± 3.2‡	−2.7 ± 3.5‡	−2.7 ± 3.5‡	0.581	0.487
	8	−2.5 ± 3.3‡	−2.7 ± 3.4‡	−3.0 ± 2.8‡	0.913	0.523
Cramps in upper abdomen	2	−1.8 ± 2.8‡	−1.2 ± 3.0†	−1.7 ± 2.9‡	0.391	0.989
	4	−2.2 ± 2.8‡	−1.5 ± 2.5‡	−2.3 ± 2.8‡	0.300	0.826
	8	−2.4 ± 2.9‡	−1.8 ± 2.7‡	−2.4 ± 3.1‡	0.433	0.724
Chest pain	2	−1.5 ± 3.5‡	−1.9 ± 3.4†	−1.6 ± 3.8†	0.532	1.000
	4	−2.7 ± 3.1‡	−2.2 ± 3.2‡	−2.9 ± 3.2‡	0.465	0.963
	8	−2.8 ± 2.7‡	−2.6 ± 3.3‡	−3.1 ± 3.3‡	0.937	0.785
Inability to finish a regular meal	2	−2.1 ± 3.5†	−1.1 ± 3.6†	−2.6 ± 3.2‡	0.223	0.642
	4	−2.2 ± 3.1‡	−1.7 ± 3.3	−3.5 ± 3.5‡	0.386	0.126
	8	−2.9 ± 3.3†	−1.9 ± 4.1‡	−3.5 ± 3.6‡	0.126	0.429
Bitter-tasting fluid in mouth	2	−2.3 ± 3.1‡	−2.8 ± 3.0‡	−2.6 ± 2.6‡	0.721	0.689
	4	−3.1 ± 3.1‡	−3.2 ± 3.6‡	−3.3 ± 3.1‡	0.790	0.836
	8	−3.5 ± 2.8‡	−3.5 ± 3.7‡	−3.6 ± 2.8‡	0.949	0.912
Fullness after eating	2	−3.1 ± 2.6‡	−2.9 ± 2.8‡	−2.9 ± 2.7‡	0.742	0.562
	4	−4.3 ± 3.1‡	−3.3 ± 2.6‡	−3.5 ± 2.8‡	0.100	0.171
	8	−4.1 ± 2.5‡	−4.7 ± 2.9‡	−4.2 ± 2.9‡	0.255	0.754
Pressure in upper abdomen	2	−2.5 ± 3.7‡	−3.2 ± 3.7‡	−2.9 ± 4.0‡	0.273	0.393
	4	−3.2 ± 3.4‡	−4.0 ± 3.6‡	−3.9 ± 2.9‡	0.145	0.159
	8	−3.7 ± 3.6‡	−4.7 ± 3.4‡	−4.2 ± 3.6‡	0.172	0.285
Bloating in upper abdomen	2	−2.4 ± 2.8‡	−2.6 ± 3.4‡	−2.6 ± 3.2‡	0.546	0.572
	4	−3.6 ± 3.3‡	−3.3 ± 3.3‡	−3.4 ± 2.7‡	0.765	0.757
	8	−3.9 ± 3.0‡	−3.7 ± 3.0‡	−4.0 ± 2.9‡	0.888	0.872
Nausea	2	−2.5 ± 3.3‡	−2.0 ± 3.4‡	−1.9 ± 3.3†	0.565	0.436
	4	−3.8 ± 3.0‡	−2.9 ± 3.4‡	−2.9 ± 3.5‡	0.217	0.187
	8	−4.1 ± 3.2‡	−3.3 ± 3.6‡	−3.4 ± 3.3‡	0.359	0.320
Vomiting	2	−0.9 ± 3.0	−1.5 ± 3.1†	−1.2 ± 2.5†	0.546	0.845
	4	−1.0 ± 2.7‡	−1.6 ± 2.9†	−1.1 ± 2.8†	0.575	0.722
	8	−1.3 ± 2.4‡	−2.2 ± 3.3‡	−1.1 ± 2.1†	0.314	0.625
Bad breath	2	−1.5 ± 2.6†	−1.7 ± 3.6	−2.4 ± 3.3‡	0.650	0.155
	4	−2.0 ± 2.9‡	−2.6 ± 3.4‡	−2.3 ± 3.5‡	0.577	0.761
	8	−2.3 ± 2.5‡	−2.7 ± 3.2‡	−2.5 ± 3.4‡	0.624	0.913

Values are presented as mean ± standard deviation.

[1] Comparison between the placebo and low-dose HT074 groups using the Mann–Whitney U test.

[2] Comparison between the placebo and high-dose HT074 groups using the Mann–Whitney U test.

Within-group comparisons with baseline were performed using the Wilcoxon signed-rank test ($^{\dagger}p < 0.05$ and $^{\ddagger}p < 0.001$). NDI-K, Nepean Dyspepsia Index-Korean version.

Table S2. Mean changes from baseline in the remaining individual GSRS item scores.

Outcome	Week	Placebo (n = 44)	Low-dose HT074 (n = 43)	High-dose HT074 (n = 39)	p-value [1]	p-value [2]
Abdominal pain	2	−0.5 ± 0.8‡	−0.6 ± 0.9‡	−0.6 ± 0.7‡	0.742	0.547
	4	−0.8 ± 0.9‡	−1.0 ± 0.7‡	−0.9 ± 0.8‡	0.279	0.523
	8	−1.1 ± 0.9‡	−1.0 ± 0.8‡	−0.9 ± 0.8‡	0.960	0.358
Acid regurgitation	2	−0.4 ± 0.7†	−0.5 ± 0.8†	−0.6 ± 0.9‡	0.339	0.245
	4	−0.5 ± 0.9†	−0.7 ± 0.7‡	−0.6 ± 0.8‡	0.566	0.894
	8	−0.7 ± 0.8‡	−0.7 ± 0.8‡	−0.8 ± 0.9‡	0.657	0.459
Sucking sensations in the epigastrium	2	−0.2 ± 0.8	−0.1 ± 0.9	−0.6 ± 1.0†	0.863	0.060
	4	−0.5 ± 0.8†	−0.3 ± 0.9†	−0.7 ± 0.9‡	0.743	0.168
	8	−0.5 ± 0.9‡	−0.4 ± 0.8†	−0.8 ± 0.8‡	0.693	0.144
Nausea and vomiting	2	−0.3 ± 0.7†	−0.4 ± 0.7†	−0.3 ± 0.7†	0.690	0.863
	4	−0.4 ± 0.6†	−0.7 ± 0.7	−0.4 ± 0.6‡	0.064	0.705
	8	−0.5 ± 0.6‡	−0.7 ± 0.7‡	−0.5 ± 0.6‡	0.126	0.862
Borborygmus	2	−0.2 ± 0.9	−0.4 ± 0.9†	−0.3 ± 0.8†	0.202	0.346
	4	−0.3 ± 1.0†	−0.6 ± 0.9‡	−0.4 ± 0.8†	0.308	0.937
	8	−0.3 ± 0.8†	−0.7 ± 1.0‡	−0.6 ± 0.8‡	0.082	0.223
Abdominal distension	2	−0.3 ± 0.9†	−0.4 ± 1.0†	−0.4 ± 0.7†	0.567	0.878
	4	−0.5 ± 1.2†	−0.7 ± 0.8‡	−0.6 ± 0.7‡	0.633	0.582
	8	−0.6 ± 0.9‡	−0.9 ± 0.8‡	−0.7 ± 0.8‡	0.143	0.716
Eructation	2	−0.3 ± 0.9†	−0.4 ± 0.8†	−0.4 ± 0.8†	0.531	0.484
	4	−0.3 ± 0.9†	−0.5 ± 1.0†	−0.4 ± 0.8†	0.298	0.781
	8	−0.5 ± 0.9†	−0.8 ± 0.9‡	−0.5 ± 0.9†	0.137	0.807
Increased flatus	2	−0.1 ± 0.8	−0.3 ± 0.7†	−0.3 ± 0.8†	0.513	0.514
	4	−0.4 ± 0.9†	−0.3 ± 0.8†	−0.4 ± 0.8†	0.872	0.925
	8	−0.6 ± 0.9‡	−0.7 ± 0.8‡	−0.4 ± 0.8†	0.382	0.452
Decreased passage of stools	2	−0.4 ± 0.8†	−0.2 ± 0.9	−0.2 ± 0.9	0.304	0.170
	4	−0.5 ± 0.9†	−0.2 ± 1.1	−0.1 ± 1.1	0.321	0.137
	8	−0.6 ± 0.8‡	−0.4 ± 0.7†	−0.3 ± 1.1	0.242	0.150
Increased passage of stools	2	0.1 ± 0.7	0.0 ± 0.9	0.2 ± 0.8	0.654	0.552
	4	0.0 ± 0.5	0.0 ± 0.9	0.1 ± 0.6	0.834	0.905
	8	−0.1 ± 0.4†	−0.1 ± 0.7	0.1 ± 0.6	0.729	0.127
Loose stools	2	−0.2 ± 0.7	−0.2 ± 0.9	−0.3 ± 0.9	0.917	0.197
	4	−0.2 ± 0.7†	−0.2 ± 0.9	−0.5 ± 0.9†	0.661	0.166
	8	−0.1 ± 0.7	−0.3 ± 0.7†	−0.4 ± 1.0†	0.181	0.167
Urgent need for defecation	2	−0.3 ± 0.8†	−0.1 ± 0.8	−0.2 ± 0.7	0.462	0.830
	4	−0.3 ± 0.7†	−0.2 ± 0.9	−0.1 ± 0.9	0.336	0.165
	8	−0.3 ± 0.8†	−0.2 ± 0.8	−0.3 ± 0.8†	0.591	0.958
Feeling of incomplete evacuation	2	−0.3 ± 0.9	−0.3 ± 0.8†	−0.4 ± 1.0†	0.781	0.516
	4	−0.4 ± 0.9†	−0.4 ± 1.0†	−0.5 ± 1.2†	0.970	0.556
	8	−0.4 ± 0.9†	−0.6 ± 1.0†	−0.6 ± 1.1†	0.597	0.203

Values are presented as mean ± standard deviation.

[1] Comparison between the placebo and low-dose HT074 groups using the Mann–Whitney U test.

[2] Comparison between the placebo and high-dose HT074 groups using the Mann–Whitney U test.

Within-group comparisons with baseline were performed using the Wilcoxon signed-rank test (†$p < 0.05$ and ‡$p < 0.001$). GSRS, Gastrointestinal Symptom Rating Scale.

Table S3. Mean changes from baseline in FD-QOL total scores in the modified intention-to-treat population.

Outcome	Week	Placebo (n = 47)	Low-dose HT074 (n = 48)	High-dose HT074 (n = 46)	p-value [1]	p-value [2]
FD-QOL total score	2	−6.0 ± 8.9‡	−7.1 ± 8.7‡	−5.5 ± 10.7‡	0.746	0.397
	4	−6.1 ± 9.4‡	−9.7 ± 9.1‡	−6.3 ± 10.6‡	**0.034**	0.966
	8	−6.9 ± 10.0‡	−9.9 ± 10.6‡	−8.2 ± 11.7‡	0.232	0.948

Values are presented as mean ± standard deviation.

[1] Comparison between the placebo and low-dose HT074 groups using the Mann–Whitney U test.

[2] Comparison between the placebo and high-dose HT074 groups using the Mann–Whitney U test.

Within-group comparisons with baseline were performed using the Wilcoxon signed-rank test (‡$p < 0.001$). Bold p-values indicate statistically significant between-group differences ($p < 0.05$). FD-QOL, Functional Dyspepsia-Related Quality of Life.

Table S4. Mean changes from baseline in the remaining individual FD-QOL item scores.

Outcome	Week	Placebo (n = 44)	Low-dose HT074 (n = 43)	High-dose HT074 (n = 39)	p-value [1]	p-value [2]
Eating status domain						
Unable to enjoy eating/drinking like others	2	−0.3 ± 0.8†	−0.4 ± 0.9†	−0.4 ± 0.8†	0.322	0.592
	4	−0.3 ± 0.6†	−0.6 ± 0.7‡	−0.3 ± 0.8†	0.114	0.342
	8	−0.3 ± 0.7†	−0.6 ± 0.9‡	−0.4 ± 0.8†	0.093	0.773
Unpleasant meals	2	−0.3 ± 0.7†	−0.4 ± 0.7‡	−0.3 ± 0.9†	0.274	0.971
	4	−0.3 ± 0.6†	−0.5 ± 0.7‡	−0.3 ± 0.9†	0.135	0.974
	8	−0.3 ± 0.8†	−0.6 ± 0.8‡	−0.3 ± 1.0	0.134	0.943
Sensitive to foods	2	−0.6 ± 0.7‡	−0.4 ± 1.0†	−0.4 ± 0.7†	0.271	0.090
	4	−0.5 ± 0.7‡	−0.5 ± 1.0†	−0.5 ± 0.9†	0.749	0.905
	8	−0.6 ± 0.7‡	−0.6 ± 1.0†	−0.6 ± 1.0†	0.953	0.807
Liveliness status domain						
Fatigue	2	−0.4 ± 0.9†	0.0 ± 1.0	−0.4 ± 1.1†	0.210	0.880
	4	−0.3 ± 0.8‡	−0.4 ± 1.1‡	−0.5 ± 0.9‡	0.790	0.522
	8	−0.6 ± 0.8‡	−0.4 ± 1.1†	−0.7 ± 1.0‡	0.283	0.922
Feeling like lying down	2	−0.3 ± 1.0	−0.1 ± 0.8	−0.5 ± 1.0†	0.497	0.503
	4	−0.4 ± 1.0†	−0.6 ± 1.0†	−0.6 ± 1.0†	0.601	0.511
	8	−0.5 ± 1.0‡	−0.5 ± 1.0‡	−0.5 ± 1.1‡	0.925	0.897
Feel sleepy during the day	2	−0.4 ± 1.0†	−0.1 ± 1.0	−0.3 ± 0.9†	0.412	0.877
	4	−0.4 ± 0.9†	−0.1 ± 1.1	−0.3 ± 0.8†	0.194	0.624
	8	−0.5 ± 1.0†	−0.3 ± 1.1	−0.4 ± 0.8†	0.230	0.569
Psychological status domain						
Feeling of frustration	2	−0.3 ± 0.7†	−0.3 ± 1.0	−0.2 ± 0.6	0.616	0.362
	4	−0.3 ± 0.9	−0.5 ± 0.8†	−0.2 ± 0.8	0.180	0.958
	8	−0.2 ± 0.8	−0.5 ± 0.9†	−0.4 ± 0.6†	0.190	0.237
Depression	2	−0.2 ± 0.7	−0.2 ± 0.6†	−0.4 ± 0.8†	0.774	0.109
	4	−0.3 ± 0.8†	−0.4 ± 0.6‡	−0.5 ± 0.8†	0.154	0.115
	8	−0.3 ± 0.7†	−0.4 ± 0.8†	−0.4 ± 0.7†	0.363	0.236
Temper	2	−0.4 ± 0.8†	−0.2 ± 0.7	−0.2 ± 0.8	0.166	0.296
	4	−0.5 ± 0.8†	−0.4 ± 0.7‡	−0.3 ± 0.9	0.528	0.237
	8	−0.4 ± 0.9†	−0.5 ± 0.7‡	−0.4 ± 1.0†	0.583	0.933
Anxiety	2	−0.3 ± 0.9	−0.2 ± 0.9	−0.3 ± 0.8	0.815	0.542
	4	−0.3 ± 0.7†	−0.3 ± 0.8†	−0.3 ± 0.7†	0.725	0.735
	8	−0.2 ± 0.9	−0.2 ± 0.8	−0.4 ± 0.8†	0.748	0.303
Feeling of being in a dark tunnel	2	−0.3 ± 0.7†	−0.3 ± 0.6†	−0.2 ± 0.4†	0.920	0.486
	4	−0.3 ± 0.8†	−0.3 ± 0.6†	−0.1 ± 0.6	0.684	0.361
	8	−0.3 ± 0.8†	−0.2 ± 0.7	−0.2 ± 0.5	0.704	0.617
Fear for the possibility of the disease getting worse	2	−0.5 ± 0.7‡	−0.5 ± 0.8†	−0.5 ± 1.1†	0.977	0.943
	4	−0.4 ± 0.7†	−0.5 ± 0.7‡	−0.6 ± 1.1†	0.364	0.603
	8	−0.5 ± 0.7‡	−0.6 ± 0.9‡	−0.7 ± 1.0‡	0.613	0.347
Role-functioning status domain						

Difficulty in work (vocation or school)	2	−0.4 ± 0.7†	−0.3 ± 0.6†	−0.1 ± 0.7	0.488	0.082
	4	−0.3 ± 0.7†	−0.4 ± 0.7†	−0.1 ± 0.7	0.788	0.158
	8	−0.4 ± 0.8†	−0.4 ± 0.7†	−0.2 ± 0.6†	0.962	0.297
Difficulty in leisure activities	2	−0.3 ± 0.9†	−0.3 ± 0.8†	−0.1 ± 0.7	0.872	0.319
	4	−0.4 ± 0.7†	−0.3 ± 0.7†	−0.1 ± 0.8	0.727	0.128
	8	−0.3 ± 0.9†	−0.4 ± 0.8†	−0.3 ± 0.7†	0.883	0.463
Difficulty in keeping company with others	2	−0.1 ± 0.6	−0.3 ± 0.8†	−0.3 ± 0.6†	0.651	0.288
	4	−0.1 ± 0.7	−0.4 ± 0.7†	−0.2 ± 0.6†	0.134	0.550
	8	−0.2 ± 0.6	−0.3 ± 0.8†	−0.3 ± 0.6†	0.305	0.241
Hard to do things with family	2	−0.1 ± 0.7	−0.2 ± 0.7	−0.2 ± 0.8	0.517	0.437
	4	−0.2 ± 0.6	−0.2 ± 0.5†	−0.2 ± 0.7	0.637	0.747
	8	−0.2 ± 0.9	−0.2 ± 0.7	−0.3 ± 0.6†	0.931	0.423
No attempt to achieve goals	2	−0.2 ± 0.9	−0.4 ± 0.7†	−0.2 ± 0.6†	0.376	0.947
	4	−0.3 ± 0.9†	−0.5 ± 0.8†	0.0 ± 0.8	0.511	0.119
	8	−0.4 ± 1.0†	−0.4 ± 0.9†	−0.4 ± 0.6†	0.904	0.863
Powerlessness	2	−0.3 ± 0.9†	−0.4 ± 1.0†	−0.4 ± 0.7†	0.792	0.689
	4	−0.4 ± 0.7†	−0.6 ± 1.0†	−0.4 ± 0.7†	0.791	1.000
	8	−0.5 ± 0.8‡	−0.6 ± 1.0†	−0.5 ± 0.9†	0.949	0.760

Values are presented as mean ± standard deviation.

[1] Comparison between the placebo and low-dose HT074 groups using the Mann–Whitney U test.

[2] Comparison between the placebo and high-dose HT074 groups using the Mann–Whitney U test.

Within-group comparisons with baseline were performed using the Wilcoxon signed-rank test (†$p < 0.05$ and ‡$p < 0.001$). FD-QOL, Functional Dyspepsia-Related Quality of Life.

Table S5. Body weight, body mass index, and vital signs during the 8-week intervention.

Outcome	Time point	Placebo (n = 44)	Low-dose HT074 (n = 43)	High-dose HT074 (n = 39)	p-value [1]	p-value [2]
Weight (kg)	Baseline	60.1±12.3	59.7±10.1	59.7±11.2	0.917	0.673
	Week 2	60.5±12.5†	59.9±10.0	60.0±11.1†	0.988	0.620
	Week 4	60.6±12.6†	60.0±10.2	60.0±11.1†	0.985	0.704
	Week 8	59.8±12.6	59.4±9.7	59.9±11.2	0.879	0.776
Body mass index (kg/m²)	Baseline	22.5±3.8	22.5±2.9	22.7±3.6	0.953	0.948
	Week 2	22.7±3.9†	22.6±2.9	22.8±3.6†	0.953	0.966
	Week 4	22.7±3.9†	22.6±2.9	22.8±3.7†	0.890	0.945
	Week 8	22.4±3.8	22.4±2.8	22.8±3.7	0.797	0.715
Systolic blood pressure (mmHg)	Baseline	114.6±10.5	118.0±12.9	117.6±14.3	0.137	0.395
	Week 2	111.5±10.4†	116.7±13.9	115.5±15.3	0.098	0.404
	Week 4	112.4±10.4	115.5±12.4	116.5±14.0	0.184	0.103
	Week 8	110.5±9.9†	116.4±11.9	115.3±14.2	**0.015**	0.125
Diastolic blood pressure (mmHg)	Baseline	71.1±8.7	75.3±9.0	72.3±11.5	**0.022**	0.875
	Week 2	69.2±7.7†	74.2±9.3	71.4±12.3	**0.010**	0.832
	Week 4	69.8±7.6	73.6±10.6	70.4±11.7†	**0.048**	0.991
	Week 8	69.7±8.7	73.1±9.0†	71.6±9.8	0.067	0.417

Values are presented as mean ± standard deviation.

[1] Comparison between the placebo and low-dose HT074 groups using the Mann–Whitney U test.

[2] Comparison between the placebo and high-dose HT074 groups using the Mann–Whitney U test.

Within-group comparisons with baseline were performed using the Wilcoxon signed-rank test (†$p < 0.05$).

Table S6. Clinical laboratory test results during the 8-week intervention.

Outcome	Time point	Placebo (n = 44)	Low-dose HT074 (n = 43)	High-dose HT074 (n = 39)	p-value [1]	p-value [2]
White blood cell count (10^3/μL)	Baseline	6.0±1.5	5.8±1.6	6.1±1.8	0.647	0.969
	Week 4	6.3±1.7[†]	6.2±1.9	6.1±1.5	0.847	0.554
	Week 8	5.8±1.3	6.0±1.8	6.0±1.5	0.899	0.812
Red blood cell count (10^6/μL)	Baseline	4.6±0.4	4.6±0.4	4.5±0.4	0.899	0.385
	Week 4	4.6±0.4	4.6±0.4	4.5±0.4	0.621	0.184
	Week 8	4.6±0.4	4.6±0.5	4.4±0.4[†]	0.605	0.107
Hemoglobin (g/dL)	Baseline	13.6±1.5	13.8±1.4	13.4±1.6	0.879	0.258
	Week 4	13.7±1.6	13.8±1.3	13.4±1.6	0.979	0.305
	Week 8	13.6±1.6	13.8±1.5	13.3±1.6	0.923	0.329
Hematocrit (%)	Baseline	41.1±4.1	41.5±4.0	40.6±3.9	0.944	0.447
	Week 4	40.9±4.0	41.0±3.4	40.3±3.8	0.902	0.529
	Week 8	40.7±3.6	41.0±4.0	40.0±3.7[†]	0.786	0.198
Albumin (g/dL)	Baseline	4.7±0.3	4.7±0.2	4.6±0.2	0.761	0.195
	Week 4	4.7±0.2	4.7±0.2[†]	4.7±0.2	0.769	0.159
	Week 8	4.7±0.2	4.7±0.3	4.6±0.2	0.644	**0.040**
Aspartate aminotransferase (U/L)	Baseline	19.9±5.7	19.0±4.8	21.3±11.7	0.280	0.660
	Week 4	19.9±4.6	19.5±5.6	19.8±5.7	0.433	0.598
	Week 8	20.3±5.3	18.9±5.9	21.0±9.2	0.078	0.584
Alanine aminotransferase (U/L)	Baseline	16.4±9.6	16.1±11.7	20.2±27.7	0.405	0.484
	Week 4	16.4±7.0	17.0±10.8	17.5±12.1	0.573	0.619
	Week 8	17.0±10.9	16.2±15.5	17.9±11.6	0.171	0.914
Blood urea nitrogen (mg/dL)	Baseline	12.0±3.9	12.4±3.8	12.9±3.1	0.579	0.093
	Week 4	11.7±3.6	12.7±3.4	13.1±3.8	0.085	**0.046**
	Week 8	12.2±3.6	12.5±3.5	13.6±3.5	0.629	0.095
Creatinine (mg/dL)	Baseline	0.7±0.1	0.7±0.1	0.7±0.1	0.726	0.449
	Week 4	0.7±0.1	0.7±0.1	0.7±0.1	0.360	0.266
	Week 8	0.7±0.1	0.7±0.1	0.7±0.1	0.462	0.085
Glucose (mg/dL)	Baseline	92.4±11.5	89.5±10.1	98.3±14.0	0.268	**0.003**
	Week 4	92.4±11.6	92.2±12.5	96.4±14.9	0.846	0.069
	Week 8	91.3±14.5	91.3±14.6	97.3±15.0	0.774	**0.013**
Gastrin (pg/mL)	Baseline	55.9±25.6	75.5±110.2	64.4±53.1	0.964	0.718
	Week 4	60.1±37.3	67.4±61.3	61.8±48.5	0.847	0.908
	Week 8	56.4±28.5	68.4±60.5	65.8±41.4	0.477	0.079
Pepsinogen I/II ratio	Baseline	4.0±1.4	3.5±1.5	3.8±1.6	0.188	0.470
	Week 4	3.8±1.4	3.4±1.4	3.7±1.6	0.153	0.509
	Week 8	4.5±4.5	3.4±1.4	3.7±1.5	0.102	0.329

C-reactive protein (mg/dL)	Baseline	0.2±0.9	0.1±0.1	0.1±0.2	0.824	0.746
	Week 4	0.1±0.3	0.1±0.0	0.1±0.2	0.437	0.431
	Week 8	0.1±0.1	0.1±0.0	0.1±0.2	0.811	0.912

Values are presented as mean ± standard deviation.

[1] Comparison between the placebo and low-dose HT074 groups using the Mann–Whitney U test.

[2] Comparison between the placebo and high-dose HT074 groups using the Mann–Whitney U test.

Within-group comparisons with baseline were performed using the Wilcoxon signed-rank test ($^{\dagger}p < 0.05$).